These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 17311601)

  • 1. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis.
    Suh DC; Kahler KH; Choi IS; Shin H; Kralstein J; Shetzline M
    Aliment Pharmacol Ther; 2007 Mar; 25(6):681-92. PubMed ID: 17311601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of potential risk factors associated with ischaemic colitis.
    Chang L; Kahler KH; Sarawate C; Quimbo R; Kralstein J
    Neurogastroenterol Motil; 2008 Jan; 20(1):36-42. PubMed ID: 17919313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alosetron: ischemic colitis and serious complications of constipation.
    Gallo-Torres H; Brinker A; Avigan M
    Am J Gastroenterol; 2006 May; 101(5):1080-3. PubMed ID: 16696787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of small intestinal bacterial vergrowth in irritable bowel syndrome.
    Mann NS; Limoges-Gonzales M
    Hepatogastroenterology; 2009; 56(91-92):718-21. PubMed ID: 19621689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.
    Cremon C; Gargano L; Morselli-Labate AM; Santini D; Cogliandro RF; De Giorgio R; Stanghellini V; Corinaldesi R; Barbara G
    Am J Gastroenterol; 2009 Feb; 104(2):392-400. PubMed ID: 19174797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictors of the efficacy of methods for psychocorrection in patients with irritable bowel syndrome and constipation].
    Aĭvazian TA; Zaĭtsev VP; Pakhomova IV; Gusakova EV
    Vopr Kurortol Fizioter Lech Fiz Kult; 2008; (5):6-8. PubMed ID: 19069796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study.
    Hervé S; Beaugerie L; Bouhnik Y; Savoye G; Colombel JF; Dyard F; Hourmand-Ollivier I; Dao T; Vial M; Lerebours E
    Neurogastroenterol Motil; 2009 Nov; 21(11):1170-e102. PubMed ID: 19460104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population.
    Locke GR; Yawn BP; Wollan PC; Melton LJ; Lydick E; Talley NJ
    Aliment Pharmacol Ther; 2004 May; 19(9):1025-31. PubMed ID: 15113370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V; Armstead C; Landry L
    Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irritable bowel syndrome in young and elderly patients with stable asthma.
    Ekici A; Guliter S; Ekici M; Kalpaklioglu F; Kara T; Keles H; Tunckol M; Akin A; Kocyigit P
    Dig Liver Dis; 2005 Oct; 37(10):773-8. PubMed ID: 16023904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
    Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of small bowel motility in patients with irritable bowel syndrome and normal humans: an Oriental study.
    Lu CL; Chen CY; Chang FY; Lee SD
    Clin Sci (Lond); 1998 Aug; 95(2):165-9. PubMed ID: 9680498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usual medical care for irritable bowel syndrome.
    Whitehead WE; Levy RL; Von Korff M; Feld AD; Palsson OS; Turner M; Drossman DA
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1305-15. PubMed ID: 15606392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities.
    Ruigómez A; García Rodríguez LA; Panés J
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):465-9. PubMed ID: 17445753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
    Chang L; Tong K; Ameen V
    Am J Gastroenterol; 2010 Apr; 105(4):866-75. PubMed ID: 20197759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatization an independent psychosocial risk factor for irritable bowel syndrome but not dyspepsia: a population-based study.
    Koloski NA; Boyce PM; Talley NJ
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1101-9. PubMed ID: 16957517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population.
    Jung HK; Halder S; McNally M; Locke GR; Schleck CD; Zinsmeister AR; Talley NJ
    Aliment Pharmacol Ther; 2007 Aug; 26(3):453-61. PubMed ID: 17635380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.